Press Releases Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Market Closed - OTC Markets Other stock markets 10:46:09 28/06/2024 pm IST			5-day change	1st Jan Change
0.6464 ^USD	-3.52%		-28.18%	-31.96%

24/04	Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
09/02	Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Regen BioPharma : Material Event - Form 8-K	30/04	PU
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05/02	PR
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20/23/20	AQ
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08/23/08	PR
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07/23/07	AQ
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23/23/23	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	20/23/20	AQ
Regen BioPharma : Private Placement - Form 8-K	22/22/22	PU
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	22/22/22	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	18/22/18	AQ
REGEN BIOPHARMA INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	16/22/16	AQ
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events (form 8-K)	14/22/14	AQ
REGEN BIOPHARMA INC : Other Events (form 8-K)	20/22/20	AQ
REGEN BIOPHARMA INC : Other Events (form 8-K)	10/22/10	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	23/22/23	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities (form 8-K)	21/22/21	AQ
Aplastic Anemia Pipeline, Therapies, Drugs and Key pharma players involved by DelveInsight \| Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others	14/22/14	AQ
REGEN BIOPHARMA INC : Unregistered Sale of Equity Securities, Other Events (form 8-K)	17/22/17	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	21/22/21	AQ
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	19/22/19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Press Releases

Filters